Development of an endometrial ablation drug-device combination to treat heavy menstrual bleeding

Industry: Medical

Country: USA


More than 10 million women in the United States and 100 million globally experience Heavy Menstrual Bleeding (HMB). Traditional treatments such as oral medications and hormonal IUDs come with significant side effects and limited effectiveness. Existing options like endometrial ablation are complicated, requiring advanced anesthesia, which restricts their accessibility for in-office use due to cost and complexity. Consequently, many women either go untreated or resort to hysterectomy, with approximately 2-3 million hysterectomies performed worldwide for HMB, including around 400,000 in the US alone. Gynion aims to address this gap with Menorrx, a non-invasive, user-friendly, and cost-effective therapy for HMB. Designed for use by OB-GYN practitioners in office settings, Menorrx requires only local anesthesia. Powered by a proprietary formulation utilizing Trichloroacetic Acid (TCA) as its active component, Menorrx offers a promising solution to alleviate HMB symptoms.